Teplizumab

Teplizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD3
Clinical data
ATC code none
Identifiers
CAS Number 876387-05-2 N
ChemSpider none
UNII S4M959U2IJ YesY
Chemical and physical data
Formula C6462H9938N1738O2022S46
Molar mass 145.8 kg/mol
 NYesY (what is this?)  (verify)

Teplizumab (also known as MGA031 and hOKT3γ1(Ala-Ala)) is a humanized monoclonal antibody that is used as an immunosuppressive drug. The Fc region of this antibody has been engineered to have Fc receptor non-binding (FNB) properties. Teplizumab was originally developed at Columbia University, and was then further developed at MacroGenics, Inc.[1][2]

This antibody has been used in clinical trials with the aim of protecting the remaining β-cells in newly diagnosed type 1 diabetes mellitus patients,[3] but "these agents [i. e. anti-CD3-antibodies] alone do not restore normal glucose control".[4]

Eli Lilly licensed the drug back in 2007 from MacroGenics with a $41 million upfront and a billion dollars pledged for milestones.

It is in Phase-3 clinical trials for Type-1 DM. One-year data from one phase III trial was disappointing.[5]

See also

References

  1. ↑ Woodle ES, Bluestone JA, Zivin RA, Jolliffe LK, Auger J, Xu D, Thistlethwaite JR (June 1998). "Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience". Transplant. Proc. 30 (4): 1369–70. doi:10.1016/S0041-1345(98)00278-4. PMID 9636555.
  2. ↑ Brown WM (April 2006). "Anti-CD3 antibody MacroGenics Inc.". Curr Opin Investig Drugs. 7 (4): 381–8. PMID 16625825.
  3. ↑ Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA (June 2005). "A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes". Diabetes. 54 (6): 1763–9. doi:10.2337/diabetes.54.6.1763. PMID 15919798.
  4. ↑ Kaufman A, Herold KC (May 2009). "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/metabolism Research and Reviews. 25 (4): 302–6. doi:10.1002/dmrr.933. PMID 19319985.
  5. ↑ "MacroGenics and Lilly Ponder Future of Diabetes mAb after Phase III Flop". 21 Oct 2010.


This article is issued from Wikipedia - version of the 9/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.